Sugi Predict

Sugi Predict / Compounds / Capivasertib

Capivasertib

Capivasertib

SCHEMBL391382

NC1(C(=O)N[C@H](CCO)c2ccc(Cl)cc2)CCN(c2ncnc3[nH]ccc23)CC1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

AKT1AKT2AKT3

The experimentally established mechanism targets of Capivasertib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ AKT1 known ✓ P31749 20/20 1.00
▸ AKT2 known ✓ P31751 8/20 1.00
▸ AKT3 known ✓ Q9Y243 8/20 1.00
▸ ROCK2 O75116 8/20 1.00
▸ PRKD3 O94806 2/20 1.00
▸ LATS1 O95835 2/20 1.00
▸ PRKCB P05771 2/20 1.00
▸ RET P07949 2/20 1.00
▸ FGFR1 P11362 2/20 1.00
▸ PRKCA P17252 2/20 1.00
▸ PRKACA P17612 2/20 1.00
▸ PRKACB P22694 2/20 1.00
▸ GRK2 P25098 2/20 1.00
▸ CLK1 P49759 2/20 1.00
▸ LIMK1 P53667 2/20 1.00
▸ LIMK2 P53671 2/20 1.00
▸ PRKAG1 P54619 2/20 1.00
▸ PRKCQ Q04759 2/20 1.00
▸ PRKCD Q05655 2/20 1.00
▸ PRKAA1 Q13131 2/20 1.00

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Capivasertib SCHEMBL390243 1.00 AKT1 (1.00) AKT1ROCK2AKT2AKT3PRKD3
Capivasertib SCHEMBL31360985 1.00 AKT1 (1.00) AKT1ROCK2AKT2AKT3PRKD3
Capivasertib SCHEMBL29557103 1.00 AKT1 (1.00) AKT1ROCK2AKT2AKT3PRKD3
Capivasertib SCHEMBL390244 1.00 AKT1 (1.00) AKT1ROCK2AKT2AKT3PRKD3
SCHEMBL386620 0.95 AKT1 (1.00) AKT1ROCK2AKT2AKT3PRKD3
SCHEMBL386619 0.95 AKT1 (1.00) AKT1ROCK2AKT2AKT3PRKD3
SCHEMBL390401 0.95 AKT1 (1.00) AKT1ROCK2AKT2AKT3PRKD3
SCHEMBL391567 0.93 AKT1 (1.00) AKT1ROCK2AKT2AKT3PRKD3
SCHEMBL393210 0.93 AKT1 (1.00) AKT1ROCK2AKT2AKT3PRKD3
SCHEMBL21619156 0.93 AKT1 (1.00) AKT1ROCK2AKT2AKT3PRKD3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120190679-A1 Novel Protein Kinase B Inhibitors - 060 ASTRAZENECA AB (SE) 2012-07-26 — — US claimed
US-12252495-B2 Protein kinase B inhibitors ASTRAZENECA AB (SE) 2025-03-18 — — US disclosed
US-20240109902-A1 PROTEIN KINASE B INHIBITORS ASTRAZENECA AB (SE) 2024-04-04 — — US disclosed
US-11760760-B2 Protein kinase B inhibitors ASTRAZENECA AB (SE) 2023-09-19 — — US disclosed
US-11760760-B2 Protein kinase B inhibitors ASTRAZENECA AB (SE) 2023-09-19 — — US disclosed
US-11760760-B2 Protein kinase B inhibitors ASTRAZENECA AB (SE) 2023-09-19 — — US disclosed
US-20220220116-A1 PROTEIN KINASE B INHIBITORS ASTRAZENECA AB (SE) 2022-07-14 — — US disclosed
US-20220220116-A1 PROTEIN KINASE B INHIBITORS ASTRAZENECA AB (SE) 2022-07-14 — — US disclosed
US-11236095-B2 Protein kinase B inhibitors ASTRAZENECA AB (SE) 2022-02-01 — — US disclosed
US-11236095-B2 Protein kinase B inhibitors ASTRAZENECA AB (SE) 2022-02-01 — — US disclosed
US-20120190679-A1 Novel Protein Kinase B Inhibitors - 060 ASTRAZENECA AB (SE) 2012-07-26 — — US disclosed
US-20120190679-A1 Novel Protein Kinase B Inhibitors - 060 ASTRAZENECA AB (SE) 2012-07-26 — — US disclosed
US-20120190679-A1 Novel Protein Kinase B Inhibitors - 060 ASTRAZENECA AB (SE) 2012-07-26 — — US disclosed
US-8101623-B2 Substituted pyrrolo[2,3-d]pyrimidine as a protein kinase B inhibitor ASTRAZENECA AB (SE) 2012-01-24 — — US disclosed
US-8101623-B2 Substituted pyrrolo[2,3-d]pyrimidine as a protein kinase B inhibitor ASTRAZENECA AB (SE) 2012-01-24 — — US disclosed
US-8101623-B2 Substituted pyrrolo[2,3-d]pyrimidine as a protein kinase B inhibitor ASTRAZENECA AB (SE) 2012-01-24 — — US disclosed
US-20090163524-A1 Novel Protein Kinase B Inhibitors - 060 ASTRAZENECA AB (SE) 2009-06-25 — — US disclosed
US-20090163524-A1 Novel Protein Kinase B Inhibitors - 060 ASTRAZENECA AB (SE) 2009-06-25 — — US disclosed
US-20090163524-A1 Novel Protein Kinase B Inhibitors - 060 ASTRAZENECA AB (SE) 2009-06-25 — — US disclosed
WO-2009047563-A1 PYRROLO [2, 3 -D] PYRIMIDIN DERIVATIVES AS PROTEIN KINASE B INHIBITORS ASTRAZENECA AB (SE) 2009-04-16 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12252495-B2 Protein kinase B inhibitors PRKAR2B, PRKCB, AKT1 AKT1 3/4885AKT2 4/4885AKT3 26/4885
US-20220220116-A1 PROTEIN KINASE B INHIBITORS PRKAR2B, PRKCB, AKT1 AKT1 3/4885AKT2 4/4885AKT3 26/4885
US-20240109902-A1 PROTEIN KINASE B INHIBITORS PRKAR2B, PRKCB, AKT1 AKT1 3/4885AKT2 4/4885AKT3 26/4885
US-20090163524-A1 Novel Protein Kinase B Inhibitors - 060 PRKAR2B, PRKCB, MAP3K20 AKT1 4/4885AKT2 6/4885AKT3 16/4885
US-20120190679-A1 Novel Protein Kinase B Inhibitors - 060 PRKAR2B, PRKCB, MAP3K20 AKT1 4/4885AKT2 6/4885AKT3 16/4885
US-11236095-B2 Protein kinase B inhibitors PRKAR2B, PRKCB, AKT1 AKT1 3/4885AKT2 4/4885AKT3 26/4885
US-11760760-B2 Protein kinase B inhibitors PRKAR2B, PRKCB, AKT1 AKT1 3/4885AKT2 4/4885AKT3 26/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.